Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society of Hematology (ASH) Annual Meeting
The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
Demonstrate significant bleed reduction in hemophilia A and B
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
Multi-ethnic innovation helps all complexions appear clearer and more uniform
Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market
Subscribe To Our Newsletter & Stay Updated
